ArticleJCI insight2017
Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI.
Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- Intramuscular Fat as a Biomarker of Muscle Health: Strengths, Limitations and Open Challenges.Journal of cachexia, sarcopenia and muscle · 2026Review
- Evaluation of renal masses with CEST MRI: Protocol optimization and preliminary results.Magnetic resonance in medicine · 2025Article
- Tumour sampling conditions perturb the metabolic landscape of clear cell renal cell carcinoma.Nature communications · 2025Article
- Adaptations of lipid metabolism in low-grade clear cell renal cell carcinoma are linked to cholesteryl ester accumulation.Scientific reports · 2025Article
- A pilot metabolomics study on clear cell renal cell carcinoma.BMC urology · 2025Article
- In Pursuit of KI-RADS: Toward a Single, Evidence-based Imaging Classification of Renal Masses.Radiology · 2025Review
- Is fat quantification based on proton density fat fraction useful for differentiating renal tumor types?Abdominal radiology (New York) · 2025Article
- Immunometabolic coevolution defines unique microenvironmental niches in ccRCC.Cell metabolism · 2023Article
- Coordinated reprogramming of renal cancer transcriptome, metabolome and secretome associates with immune tumor infiltration.Cancer cell international · 2023Article
- A chemokine network of T cell exhaustion and metabolic reprogramming in renal cell carcinoma.Frontiers in immunology · 2023Article
- In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma.Science advances · 2022Article
- In Vivo Renal Lipid Quantification by Accelerated Magnetic Resonance Spectroscopic Imaging at 3T: Feasibility and Reliability Study.Metabolites · 2022Article
- Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma.Frontiers in oncology · 2022Review
- Biomarker Screening and Prognostic Significance Analysis for Renal Cell Carcinoma.International journal of general medicine · 2021Article
- The Heterogeneity Metabolism of Renal Cell Carcinomas.Advances in experimental medicine and biology · 2021Article
- Article
- Pivotal biomarker expression and drug screening in advanced ccRCC.Clinical and translational medicine · 2020Article
- Investigation of Plasma Metabolic and Lipidomic Characteristics of a Chinese Cohort and a Pilot Study of Renal Cell Carcinoma Biomarker.Frontiers in oncology · 2020Article
- Recent Advances of Bioresponsive Nano-Sized Contrast Agents for Ultra-High-Field Magnetic Resonance Imaging.Frontiers in chemistry · 2020Review
- Uptake of HDL-cholesterol contributes to lipid accumulation in clear cell renal cell carcinoma.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundDysregulated lipid and glucose metabolism in clear cell renal cell carcinoma (ccRCC) has been implicated in disease progression, and whole tumor tissue-based assessment of these changes is challenged by the tumor heterogeneity. We studied a noninvasive quantitative MRI method that predicts metabolic alterations in the whole tumor.
methodsWe applied Dixon-based MRI for in vivo quantification of lipid accumulation (fat fraction [FF]) in targeted regions of interest of 45 primary ccRCCs and correlated these MRI measures to mass spectrometry-based lipidomics and metabolomics of anatomically colocalized tissue samples isolated from the same tumor after surgery.
resultsIn vivo tumor FF showed statistically significant (P < 0.0001) positive correlation with histologic fat content (Spearman correlation coefficient, ρ = 0.79), spectrometric triglycerides (ρ = 0.56) and cholesterol (ρ = 0.47); it showed negative correlation with free fatty acids (ρ = -0.44) and phospholipids (ρ = -0.65). We observed both inter- and intratumoral heterogeneity in lipid accumulation within the same tumor grade, whereas most aggressive tumors (International Society of Urological Pathology [ISUP] grade 4) exhibited reduced lipid accumulation. Cellular metabolites in tumors were altered compared with adjacent renal parenchyma.
conclusionOur results support the use of noninvasive quantitative Dixon-based MRI as a biomarker of reprogrammed lipid metabolism in ccRCC, which may serve as a predictor of tumor aggressiveness before surgical intervention.
fundingNIH R01CA154475 (YZ, MF, PK, IP), NIH P50CA196516 (IP, JB, RJD, JAC, PK), Welch Foundation I-1832 (JY), and NIH P01HL020948 (JGM).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.